Session I. The genesis of CLL

Chairs: Nicholas Chiorazzi, Kostas Stamatopoulos
Introduction by Federico Caligaris-Cappio

• Exploring the roads to CLL, by Freda Stevenson
• MBL: Always a one-way ticket to CLL?, by Lydia Scarfo
• CLL: One entity or more? Diagnostic considerations, by Andy Rawstron

Session II. Disease trajectories: Outcomes, possible explanations and clinical implications

Chairs: Michael Doubek, Robin Foa

• Spontaneous regression, by Tatjana Stankovic
• Clonal evolution: How is it reflected at the genome?, by Catherine J. Wu
• Richter transformation, by Davide Rossi
• CHIP and second primary myeloid malignancies, by Panagiotis Baliakas

Session III. Resistance to apoptosis

Chairs: Eric Eldering, Alan Ramsay

• The anti-apoptotic phenotype: Cell-intrinsic drivers, by Stephan Stilgenbauer
• The anti-apoptotic phenotype: Cell-extrinsic drivers, by Dimitar Efremov
• Promoting apoptosis in CLL: Clinical overview, by John Seymour

Session V. Networking and collaboration: Why and how

Chairs: Eva Kimby, Emili Montserrat

• US initiatives, by Anthony Mato
• The ERIC CLL Database, by Anastasia Chatzidimitriou
• CLL within HARMONY, by Francesc Bosch
• EHA links to EU initiatives and infrastructures, by Ulrich Jaeger

Round table discussion: Frontline treatment: State-of-the-art

Chairs: Michael Hallek, John Seymour
Discussants: Florence Cymbalista, Matthew Davids, Kirsten Fischer, George Follows, Alessandra Tedeschi, William Wierda, Jennifer Woyach

Round table discussion: Management of relapsed/refractory disease: State-of-the-art

Chairs: Jennifer Brown, Peter Hillmen
Discussants: Antonio Cuneo, Barbara Eichhorst, Arnon Kater, Stephen Schuster, Michel van Gelder